{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:45:02Z","timestamp":1792071902092,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10147-024-02541-z","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T14:02:26Z","timestamp":1714658546000},"page":"700-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology"],"prefix":"10.1007","volume":"29","author":[{"given":"Kenji","family":"Tsuchihashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Nio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetaka","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-6772","authenticated-orcid":false,"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2541_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JOP.2014.001492","volume":"11","author":"D Weycker","year":"2015","unstructured":"Weycker D, Li X, Edelsberg J et al (2015) Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 11:47\u201354","journal-title":"J Oncol Pract"},{"key":"2541_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00520-023-08071-0","volume":"31","author":"B Leon Rapoport","year":"2023","unstructured":"Leon Rapoport B, Garcia-Morillo M, Font C et al (2023) A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative. Support Care Cancer 31:628","journal-title":"Support Care Cancer"},{"key":"2541_CR3","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111\u2013v118","journal-title":"Ann Oncol"},{"key":"2541_CR4","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"2541_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors version 3. 2024. Accessed 7 Mar 2024"},{"key":"2541_CR6","unstructured":"Medical Information Network Distribution System: MINDS guideline center. http:\/\/minds.jcqhc.or.jp\/n\/st.php. Accessed 7 Mar 2024"},{"key":"2541_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66:719\u2013725","journal-title":"J Clin Epidemiol"},{"key":"2541_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Sch\u00fcnemann HJ, Oxman AD et al (2013) GRADE guidelines: 15. Going from evidence to recommendation\u2014determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol 66:726\u2013735","journal-title":"J Clin Epidemiol"},{"key":"2541_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jnci\/93.1.31","volume":"93","author":"R Garc\u00eda-Carbonero","year":"2001","unstructured":"Garc\u00eda-Carbonero R, Mayordomo JI, Tornamira MV et al (2001) Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 93:31\u201338","journal-title":"J Natl Cancer Inst"},{"key":"2541_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1179\/joc.2004.16.3.288","volume":"16","author":"O Er","year":"2004","unstructured":"Er O, Coskun HS, Altinbas M et al (2004) Meropenem +\/\u2212 granulocyte colony stimulating factor in the treatment of febrile neutropenic patients with cancer: prospective randomized study. J Chemother 16:288\u2013292","journal-title":"J Chemother"},{"key":"2541_CR11","first-page":"CD003039","volume":"2014","author":"R Mhaskar","year":"2014","unstructured":"Mhaskar R, Clark OAC, Lyman G et al (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014:CD003039","journal-title":"Cochrane Database Syst Rev"},{"key":"2541_CR12","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02541-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02541-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02541-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T08:24:45Z","timestamp":1716798285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02541-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2541"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02541-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kenji Tsuchihashi has received honoraria from Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Taiho Pharmaceutical Co. Ltd., and Novartis Pharmaceutical. K.K. Yukinori Ozaki has received honoraria from Daiichi Sankyo Co. Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., and Kyowa Kirin Co. Ltd. Eiki Ichihara has received honoraria from Eli Lilly Japan K.K. and research funding from MSD K.K., Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Co. Ltd. Yuji Miura has received honoraria from Ono Pharmaceutical Co. Ltd., MSD K.K., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., and Bristol Myers Squibb Co. Ltd., and research funding from MSD K.K. and Ono Pharmaceutical Co. Ltd. Shingo Yano has received research funding from Otsuka Pharmaceutical Co. Ltd. Dai Maruyama has received honoraria from Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co. Ltd., Eisai Co. Ltd., Mundipharma, Kyowa Kirin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Zenyaku Holdings Co. Ltd., MSD K.K., SymBio Pharmaceutical Ltd., Sanofi K.K., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., AstraZeneca K.K., Bristol Myers Squibb Co. Ltd., and Genmab K.K., and research funding from Amgen K.K., Astellas Pharma Inc., Biopharma Co. Ltd., Novartis Pharmaceutical K.K., Kyowa Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Sanofi K.K., Bristol Myers Squibb Co. Ltd., AbbVie Inc., Eisai Co. Ltd., MSD K.K., Taiho Pharmaceutical Co. Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., and Genmab K.K. Tetsuhiro Yoshinami has received honoraria from Kyowa Kirin Co. Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co., Eli Lilly Japan K.K., MSD K.K., AstraZeneca K.K., and Eisai Co. Ltd. Takashi Motohashi has received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., and Myriad Genetics G.K. Toshio Kubo has received honoraria from Chugai Pharmaceutical Co. Takahiro Kimura has received honoraria from Sanofi K.K. Shinji Nakao has received honoraria from Kyowa Kirin Co., Ltd. Atsushi Sato has received honoraria from Chugai Pharmaceutical Co. and Taiho Pharmaceutical Co. Ltd., and a scholarship donation from Chugai Pharmaceutical Co. and Taiho Pharmaceutical Co. Ltd. Toshimi Takano has received honoraria from Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co., and Eli Lilly Japan K.K. Eishi Baba has received honoraria from Chugai Pharmaceutical Co. Ltd. and Daiichi Sankyo Co.Ltd., and research funding from Taiho Pharmaceutical Co. Ltd. and Chugai Pharmaceutical Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}